110 related articles for article (PubMed ID: 18096712)
1. Bronchoalveolar cellular analysis in scleroderma lung disease: does Sutton's law hold?
Baughman RP; Raghu G
Am J Respir Crit Care Med; 2008 Jan; 177(1):2-3. PubMed ID: 18096712
[No Abstract] [Full Text] [Related]
2. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
Kowal-Bielecka O; Kowal K; Rojewska J; Bodzenta-Lukaszyk A; Siergiejko Z; Sierakowska M; Sierakowski S
Ann Rheum Dis; 2005 Sep; 64(9):1343-6. PubMed ID: 16100339
[TBL] [Abstract][Full Text] [Related]
3. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.
Strange C; Bolster MB; Roth MD; Silver RM; Theodore A; Goldin J; Clements P; Chung J; Elashoff RM; Suh R; Smith EA; Furst DE; Tashkin DP;
Am J Respir Crit Care Med; 2008 Jan; 177(1):91-8. PubMed ID: 17901414
[TBL] [Abstract][Full Text] [Related]
4. Gene expression in bronchoalveolar lavage cells from scleroderma patients.
Luzina IG; Atamas SP; Wise R; Wigley FM; Xiao HQ; White B
Am J Respir Cell Mol Biol; 2002 May; 26(5):549-57. PubMed ID: 11970906
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide versus placebo in scleroderma lung disease.
Tashkin DP; Elashoff R; Clements PJ; Goldin J; Roth MD; Furst DE; Arriola E; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M;
N Engl J Med; 2006 Jun; 354(25):2655-66. PubMed ID: 16790698
[TBL] [Abstract][Full Text] [Related]
6. [Phenotype of lymphocytes in bronchoalveolar lavage fluid of patients with lung fibrosis in the course of scleroderma].
Domagała-Kulawik J; Hoser G; Doboszyńska A; Kawiak J; Droszcz W
Pneumonol Alergol Pol; 1995; 63(7-8):382-8. PubMed ID: 8520554
[TBL] [Abstract][Full Text] [Related]
7. [Chemiluminescence measurements of bronchoalveolar lavage cells in patients with collagenosis].
Witt C; Winsel K; Apostoloff E; Brenke A; Hiepe F; Renner H
Z Erkr Atmungsorgane; 1990; 175(2):81-7. PubMed ID: 2264364
[TBL] [Abstract][Full Text] [Related]
8. [Bronchoalveolar lavage in patients with systemic scleroderma and systemic lupus erythematosus: characterization of cell activity by cytofluorometry, chemiluminescence and differential cell count].
Witt C; Neuhaus K; Winsel K; Brenke A; Hiepe F; Volk HD
Z Erkr Atmungsorgane; 1991; 176(1):21-9. PubMed ID: 2053369
[TBL] [Abstract][Full Text] [Related]
9. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease.
Kowal-Bielecka O; Distler O; Kowal K; Siergiejko Z; Chwiećko J; Sulik A; Gay RE; Łukaszyk AB; Gay S; Sierakowski S
Arthritis Rheum; 2003 Jun; 48(6):1639-46. PubMed ID: 12794832
[TBL] [Abstract][Full Text] [Related]
10. Educational case report - self assessment.
Walker T
Cytopathology; 2002 Oct; 13(5):329. PubMed ID: 12421450
[No Abstract] [Full Text] [Related]
11. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L
Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
[TBL] [Abstract][Full Text] [Related]
12. [Interstitial lung manifestations in systemic scleroderma. Correlation between alveolitis, autoantibodies and clinical manifestations].
Witt C; Hiepe F; Brenke A; Romberg B; Apostoloff E
Z Arztl Fortbild (Jena); 1994 Nov; 88(11):867-71. PubMed ID: 7839707
[No Abstract] [Full Text] [Related]
13. [Diagnostic value of secretory products of eosinophils and neutrophils in bronchoalveolar lavage in patients with idiopathic lung fibrosis].
Pohl WR; Schenk E; Umek H; Micksche M; Kummer F; Köhn H
Wien Klin Wochenschr; 1993; 105(14):387-92. PubMed ID: 8396288
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.
Silver RM; Warrick JH; Kinsella MB; Staudt LS; Baumann MH; Strange C
J Rheumatol; 1993 May; 20(5):838-44. PubMed ID: 8336309
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
16. Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial?
Wells AU; Latsi P; McCune WJ
Am J Respir Crit Care Med; 2007 Nov; 176(10):952-3. PubMed ID: 17984310
[No Abstract] [Full Text] [Related]
17. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
Várai G; Earle L; Jimenez SA; Steiner RM; Varga J
J Rheumatol; 1998 Jul; 25(7):1325-9. PubMed ID: 9676764
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide in systemic sclerosis: light and shadows.
Vlachoyiannopoulos PG; Ioannidis JP
Clin Exp Rheumatol; 2004; 22(5):551-2. PubMed ID: 15485005
[No Abstract] [Full Text] [Related]
19. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients.
Luzina IG; Atamas SP; Wise R; Wigley FM; Choi J; Xiao HQ; White B
Arthritis Rheum; 2003 Aug; 48(8):2262-74. PubMed ID: 12905481
[TBL] [Abstract][Full Text] [Related]
20. T-cell activation in the lungs of patients with systemic sclerosis and its relation with pulmonary fibrosis.
Bresser P; Jansen HM; Weller FR; Lutter R; Out TA
Chest; 2001 Jul; 120(1 Suppl):66S-68S. PubMed ID: 11451930
[No Abstract] [Full Text] [Related]
[Next] [New Search]
